Novartis AG (NVS) Shares Sold by Osborn Williams & Donohoe LLC
Osborn Williams & Donohoe LLC lessened its holdings in shares of Novartis AG (NYSE:NVS) by 2.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 53,645 shares of the company’s stock after selling 1,070 shares during the period. Osborn Williams & Donohoe LLC’s holdings in Novartis AG were worth $4,606,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Westwood Holdings Group Inc. grew its holdings in shares of Novartis AG by 5.6% during the first quarter. Westwood Holdings Group Inc. now owns 5,405 shares of the company’s stock worth $401,000 after purchasing an additional 285 shares during the last quarter. GFS Advisors LLC grew its holdings in shares of Novartis AG by 6.5% during the second quarter. GFS Advisors LLC now owns 21,314 shares of the company’s stock worth $1,779,000 after purchasing an additional 1,300 shares during the last quarter. Union Bankshares Corp grew its holdings in shares of Novartis AG by 0.3% during the second quarter. Union Bankshares Corp now owns 37,521 shares of the company’s stock worth $3,132,000 after purchasing an additional 99 shares during the last quarter. Mechanics Bank Trust Department bought a new stake in shares of Novartis AG during the second quarter worth $389,000. Finally, ProVise Management Group LLC grew its holdings in shares of Novartis AG by 12.2% during the second quarter. ProVise Management Group LLC now owns 85,041 shares of the company’s stock worth $7,099,000 after purchasing an additional 9,227 shares during the last quarter. Institutional investors own 10.93% of the company’s stock.
Several brokerages have recently commented on NVS. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a report on Tuesday, October 10th. Zacks Investment Research cut Novartis AG from a “buy” rating to a “hold” rating in a report on Friday, October 6th. BidaskClub upgraded Novartis AG from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Finally, Cowen and Company set a $90.00 target price on Novartis AG and gave the stock a “hold” rating in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $84.13.
Novartis AG (NVS) traded down 0.31% during trading on Wednesday, reaching $86.07. The company had a trading volume of 625,679 shares. The firm’s 50 day moving average price is $85.27 and its 200 day moving average price is $81.90. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90. The firm has a market capitalization of $201.65 billion, a PE ratio of 31.42 and a beta of 0.73.
Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.06. The business had revenue of $12.24 billion for the quarter, compared to analyst estimates of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. Novartis AG’s quarterly revenue was down 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS. Analysts anticipate that Novartis AG will post $4.75 earnings per share for the current year.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.